Market Overview

UPDATE: Jefferies & Company Reiterates Buy Rating, Raises PT on Pfizer

Share:
Related PFE
Cramer's Guide To Profit From Market Rotations
The Street Has Finally Recognized The Exelixis Clinical Program Potential

In a report published Wednesday, Jefferies & Company reiterated its Buy rating on Pfizer (NYSE: PFE), and raised its price target from $27.00 to $31.00.

Jefferies & Company noted, “We see Pharmaceuticals as remaining attractive in 2013, but unlikely to return the same level of relative performance as in 2012. Our Top Pick in the US is AbbVie, with Novartis being our most preferred name in Europe. Sanofi, Roche, Pfizer and Bristol-Myers remain high conviction Buy ratings. We continue to point to Eli Lilly and GlaxoSmithKline as our least preferred names.”

Pfizer closed on Tuesday at $26.74.

Latest Ratings for PFE

DateFirmActionFromTo
Sep 2017Morgan StanleyUpgradesEqual-WeightOverweight
Aug 2017BMO CapitalUpgradesMarket PerformOutperform
Jul 2017Credit SuisseMaintainsNeutral

View More Analyst Ratings for PFE
View the Latest Analyst Ratings

Posted-In: Jefferies & CompanyAnalyst Color Price Target Analyst Ratings

 

Related Articles (PFE)

View Comments and Join the Discussion!
Loading...
Loading...